Biomea Fusion reveals obesity drug progress in exclusive JPMorgan call

Biomea Fusion, Inc. recently took part in a private conference call with JPMorgan clients. The discussion focused on the company's oral GLP-1 receptor antagonist, a drug being developed for obesity treatment. Key executives, including the interim CEO, joined the session to outline progress and future plans.

The call was led by Anupam Rama, a senior biotech analyst at JPMorgan Chase & Co. Joyce Zhou, another analyst from the bank's research division, also participated. Attendance was restricted, with only approved JPMorgan clients allowed to join.

Representing Biomea Fusion were Michael J. Hitchcock, the interim CEO and director, along with Thorsten Kirschberg, executive vice president of research. Ramses Erdtmann, the company's co-founder, president, chief operating officer, and director, was also present. The team provided updates on their obesity programme, particularly the Phase I trial of their oral GLP-1 receptor antagonist. While no Phase I data has yet been published, the company confirmed that initial results for the obesity treatment are expected in the second quarter of 2026. No details were shared about potential stock price movements following the announcement.

The call highlighted Biomea Fusion's ongoing work in obesity treatment, with a focus on their experimental oral drug. Investors and analysts now await the first Phase I results, due in mid-2026. The company has not released further specifics on trial timelines or financial impacts at this stage.